May 9, 2025 05:51 AM GMT Shenzhen New Industries | Asia Pacific China BEST Conference 2025 Feedback Key Takeaways Targeting single-digit China growth for 2025, with faster analyzer than reagent growth: For analyzer installations, SNIBE continues to target 2,000 units (¾ being high throughput models) and 200 TLAs in 2025. Reagent ASP should have bottomed in 2Q25 (~5% QoQ decline from 1Q25) hence the YoY price impacts will be largely digested by 4Q25. As for volume, mgmt expects sequentially improving volume ...

Company Overview - Outset Medical, Inc. is a medical technology company focused on pioneering technology to reduce the cost and complexity of dialysis [3] - The Tablo® Hemodialysis System is FDA cleared for use from the hospital to the home, representing a significant technological advancement in dialysis [3] - Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by anyone [3] Technological Innovation - The integration of water purification and on-demand dialysate production enables Tablo to function as a "dialysis clinic on wheels" [3] - Tablo features 2-way wireless data transmission and a proprietary data analytics platform, promoting a holistic approach to dialysis care [3] Upcoming Events - Members of Outset's management will participate in the RBC Capital Markets Global Health Care conference on May 20, 2025, at 10:30 a.m. Eastern time [1] - A live and archived webcast of the session will be available on the "Investors" section of the Outset website [2]

5月8日，第二十七届中国北京国际科技产业博览会（以下简称"科博会"）在国家会议中心拉开帷幕。 《中国经营报》记者从丰台展区现场了解到，作为首都科技创新的重要承载地，丰台区在本次科博会期 间组织25家前沿科技企业参展，集中展示了人形机器人、激光低频交变磁场治疗机等近70项尖端科技成 果，全面呈现了丰台区"科技+产业+体验"深度融合的创新生态。 五大产业板块亮相 丰台展区的核心亮点在于"五大产业板块"——轨道交通、航天航空、医药大健康、低空技术及新兴产 业。这些板块集中展现了丰台区在多个领域的科技实力与产业优势。 此次科博会，丰台空间资源对接服务平台首次线下亮相。该平台通过地图交互技术整合316处优质产业 空间，为企业提供办公选址、人才公寓、商业配套等资源的"一键导航"服务，精准匹配个性化需求。丰 台区投资促进服务中心主任庄凯表示，平台将助力优化区域营商环境，成为企业落地的"加速器"。 科博会期间，丰台区通过"会展+产业"深度联动，激活资源对接与项目落地。卫星互联网产业园、北京 低空技术创新园等优质产业空间集中展示，医药大健康产业、供应链及商协会专场推介会同步举办，吸 引企业"边展示、边对接、边落地"。拜斯特医疗 ...

Making the Invisible Visible Q2 FY25 Earnings Presentation May 8, 2025 5/8/2025 1 Forward Looking Statements This supplement contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning financial results; earnings guidance; tariffs and trade wars and their impact on our customers; industry or business outlook, including for our business in China; product demand; payoff of our convertible debt; expected future financial results or per ...

Inogen, Inc. (INGN) incurred an adjusted loss per share of 11 cents for first-quarter 2025, which was narrower than the adjusted loss per share of 45 cents in the year-ago period and the Zacks Consensus Estimate of a loss of 52 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)GAAP loss per share for the quarter was 25 cents, narrower than the year-earlier loss of 62 cents.INGN’s Revenues in DetailInogen registered revenues of $82.3 million for the first quarter, up 5 ...

Group 1: Event Overview - The 27th China Beijing International Science and Technology Industry Expo opened on May 8 at the National Conference Center, with Dongcheng District showcasing a "Science and Innovation Golden Triangle" theme and inviting 35 companies to participate [1] - The Dongcheng exhibition area launched 21 new products and technologies, including 5 in the "Technology + Culture" sector, 4 in "Technology + Healthcare," and 12 in "Technology + Future Industries" [1] Group 2: Key Exhibits and Innovations - The highlight of the cultural industry section was the Poly Culture's multi-functional cultural relic holographic display cabinet, which has obtained patents for its design and a 3D holographic interactive system, allowing viewers to interact with digital models and real artifacts [1] - In the healthcare sector, Beijing Union Medical College Hospital showcased two original automated dental pulp treatment devices and a digital assessment and intervention system for frailty and sarcopenia, while MaiSheng Medical presented a miniaturized proton therapy device for cancer treatment [2] - The "Technology + Future Industries" circular exhibition area focused on four advanced fields: AI + headquarters digitization, Beidou navigation + smart cities, 6G + next-generation communication technology, and new energy and green low-carbon transformation [3] Group 3: Industry Development and Future Outlook - Dongcheng District aims to establish a new benchmark for integrated development of "Science and Innovation + Livability and Employment," focusing on chip design, healthcare, and central enterprise digitization [3] - The area is strategically developing a 10.8 square kilometer zone with a "three-axis, three-core, multi-point" layout, attracting major foreign enterprises like Intel and Qualcomm, and top financial institutions [3] - The resource aggregation in the "Science and Innovation Golden Triangle" is expected to significantly enhance the district's innovation capacity in the next two years [3]

Financial Performance & Guidance - NN's Q1 2025 net sales were $105.7 million, flat year-over-year on a pro forma basis, but down $15.5 million as reported[14, 40] - Adjusted EBITDA for Q1 2025 was $10.6 million, with an adjusted EBITDA margin of 10.0%, reconfirming FY 2025 guidance of $53-$63 million[14] - The company is lowering its 2025 net sales guidance to $430-$460 million due to GDP uncertainties, but reiterating adjusted EBITDA guidance of $53-$63 million and new business awards guidance of $60-$70 million[12] - NN initiates 2025 guidance for free cash flow at $14 to $16 million[12] Business Transformation & New Business - NN is launching 120 new programs in 2025, expected to add approximately $55 million in peak annual sales[11] - The company's new business program has secured $160 million of new business from January 2023 to May YTD 2025[16, 18, 21] - NN Europe achieved $6.7 million in new wins in Q1 2025, with an estimated total program value of over $50 million[25] - The company's working capital has been reduced by 20%, or $21.6 million, over the last two years, from $106.4 million in Q1 2023 to $84.8 million in Q1 2025[37, 38] Cost Reduction & Operational Efficiency - NN has reduced its global staff by 16%, or 525 people, over two years, with further reductions planned for 2025[29, 33] - The company is implementing a $6.5 million payroll reduction plan in 2025[33] - NN is advancing its organic transition into non-auto areas by leveraging $340 million of installed assets and investing $10-$14 million additional cash capex per year[12]

LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing ...

Core Insights - Outset Medical, Inc. reported a 6% increase in revenue for Q1 2025, reaching $29.8 million compared to $28.2 million in Q1 2024, driven by strong performance in product and service revenues [4][9] - The company continues to demonstrate operational improvements, with a significant reduction in operating expenses by 39% year-over-year, contributing to a path toward profitability [6][11] - The installed base of the Tablo system is growing, with a notable increase in recurring revenue from consumables and services, which rose by 20% to $22.7 million [3][4][9] Financial Performance - Product revenue increased by 4% to $21.3 million, while service and other revenue grew by 9% to $8.5 million compared to the same period last year [4] - Gross profit for Q1 2025 was $11.1 million, a 35% increase from $8.2 million in Q1 2024, with gross margin improving to 37.2% from 29.2% [5][9] - The net loss narrowed to $25.8 million, or ($3.66) per share, compared to a net loss of $39.9 million, or ($11.77) per share in the prior year [8][9] Operational Highlights - The company shipped its 3 millionth Tablo treatment during the quarter, marking a significant milestone with 1 million treatments added over the past year [9] - Operating expenses were reduced to $27.5 million from $45.1 million in Q1 2024, with R&D expenses at $5.5 million, S&M expenses at $13.7 million, and G&A expenses at $8.3 million [6][8] - Non-GAAP operating expenses were reported at $24.6 million, reflecting ongoing efforts to streamline operations [7] Cash Position and Guidance - Total cash, including restricted cash and short-term investments, was $192 million as of March 31, 2025, following a financing round that provided approximately $210 million in cash [10][25] - The company reiterated its 2025 revenue guidance of $115 million to $125 million and expects to use less than $50 million in cash for the year, a significant reduction from $103 million used in 2024 [11]

Koninklijke Philips N.V. (PHG) reported earnings of €0.08 cents per share in the first quarter of 2025, which increased from the year-ago quarter’s loss of €1.07 per share.The company’s sales decreased 1% on a year-over-year basis to €4.1 billion.Comparable sales declined 2% year over year, including a double-digit decline in China. The 1% growth in Personal Health was more than offset by a 4% decline in Diagnosis & Treatment on the back of a high comparison base. Connected Care sales were in line with the ...